Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

AACR 2009: Molecular profiling of tumours to find potential targets and treatments for refractory cancers

Share :

AACR 2009

18 - 22 Apr 2009
Published: 1 May 2009
Views: 17527
Rating:
Save
Dr Daniel Von Hoff - Chief Scientific Officer, Scottsdale Healthcare and U.S. Oncology Research
Daniel Von Hoff, M.D., senior investigator/physician-in-chief, TGen; chief scientific officer, Scottsdale Healthcare and U.S. Oncology Research, speaking at AACR 2009, Denver: A Pilot Study Utilizing Molecular Profiling of Tumours to Find Potential Targets and Select Treatments for Their Refractory Cancers

Related Videos

New classification for identifying HR myeloma based on cytogenetic abnormalities
Dr Jill Corre - IUCT Oncopole, Toulouse, France
New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )
29 Oct 2024
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...
ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )
15 Sep 2024
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA
Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )
12 Jul 2024
ASCO 2024: Lung cancer highlights
Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...
ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )
26 Jun 2024
Best practice in HRRm testing in patients with metastatic prostate cancer
Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel...
Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )
7 Jun 2024
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024
Multiple myeloma in a resource constrained setting
Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda
Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )
22 Feb 2024
A biomarker led approach to bladder cancer
Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...
A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )
22 Oct 2023
Latest treatments in oesophageal cancer
Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA
Latest treatments in oesophageal cancer ( Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA )
5 Apr 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation